Issue of Share Options and PDMR Shareholdings

1 July 2021

Diaceutics PLC

("Diaceutics" or "the Company")

Issue of Share Options and PDMR Shareholdings

Diaceutics PLC, (AIM: DXRX), the diagnostic commercialisation company for precision testing announces the issue of share options over ordinary shares of £0.002 each in the Company ("Share Options") on 30 June 2021, to certain members of the Company's senior management team and other key staff. These share options have been issued pursuant to certain contractual share-based entitlements in place prior to the Company's IPO and are governed by the rules of the Company's Employee Share Option Plan ("ESOP").

Share Options were granted as follows:

A further 147,000 Share Options were granted to 35 employees, each of whom received 4,200 Share Options.

The Share Options vest in full after three years following date of grant subject to the grantee receiving  no more than two "unsatisfactory" performance ratings in their individual performance reviews in the three-year period from the date of grant. The exercise price of the Share Options is £0.002 per share being the nominal value of the share.

Following the grant the total number of share options outstanding granted to the Company's Directors, senior management team and key employees is 2,237,170, representing approximately 2.7% of the Company's current issued share capital of 84,068,923.

Enquiries:

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®. 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.